Drug Profile
Mesenchymal stem cell therapy - NextCell Pharma
Alternative Names: ProTransLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator NextCell Pharma
- Developer NextCell Pharma; Uppsala University
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID-19 pneumonia; Type 1 diabetes mellitus
- Phase I Pneumonia
- No development reported Renal transplant rejection
Most Recent Events
- 25 Jan 2024 NextCell plans for market approval of ProTrans via a phase III trial
- 05 Jul 2023 The Data Safety Monitoring Board approves enrolment in a high-dose cohort of a phase I trial of Pneumonia
- 16 Jun 2023 McGill University Health Centre terminates a phase II trial in COVID-19 pneumonia in Canada (IV), since DSMB recommended to end the study prematurely as recruitment goals were not being met and benefit was not influencial enough (NCT04869397)